Top Tech Companies (45)
Don't see your company?
Create a company profile
Grow Pharma is the leader in supplying unlicensed cannabis medicines in the UK. Grow Pharma was established by Grow Biotech and IPS Pharma, combining cannabis sector expertise with 18 years’ experience manufacturing and importing unlicensed medicines
JUNE Medical Group is a women-owned medical devices company with offices in the UK, USA and Sweden. The company supplies selected products from leading manufacturers, and develops its own medical instruments, including the Galaxy II self retaining retractor – an extraordinary tool featuring the world’s first ever light attachment, Galaxy II™ LUX Approved Supplier: Galaxy II is already on the system in NHS Supply Chain, The Mount Sinai Hospitals, U.S. Department of Veterans Affairs approved (DAPA number is SP0200-21-H-0057) Circle Health Group, Baylor Scott & White Health The Queens Award for Enterprise: INNOVATION 2021 Women Owned Certified JUNE Medical incl Mosaic Surgical Manufacturing Most Trusted Surgical Medical Device Company 2022 - UK Best New Business 2015 UK Entrepreneur of the Year 2017 Growth Champion by Dept Int Trade 2019 Champions of Trade BAB /US Embassy UK 2021 UK CEO of the Year 2021
We’re an innovative and forward-thinking Commercial Pharma analytics startup based in the UK. Since 2014 we’ve been focusing our efforts on providing cutting edge input to pharmaceutical organisations throughout Europe and North America. By combining years of experience in healthcare, pharmaceutical and data , we provide a powerful tool for acquiring real actionable insights to Commercial strategy, Formulary status, Salesforce effectiveness, targeting & segmentation, Sales analytics and many more.
Pulmocide is a biopharmaceutical company that specializes in tackling difficult-to-treat respiratory diseases. We focus on respiratory fungal infections that can be serious and life-threatening and have significant effects on patients’ quality of life. Our current clinical development focus is on treating patients who have not successfully responded to the standard of care and on the prophylactic treatment of lung transplant patients. Pulmocide’s innovative approach to drug development provides a novel potential therapy that has been specifically designed to treat the most common fungal lung disease, pulmonary aspergillosis. Opelconazole was designed for inhaled delivery to minimize systemic exposure and deliver a high concentration of drug with a long retention time at the site of infection. This approach could improve treatment outcomes in patients with fungal lung disease without increasing systemic side effects and without interactions with other medications. The Pulmocide team is well experienced in the discovery and development of inhaled therapies for respiratory and infectious disease indications. They have particular expertise in the identification of novel compounds that can be delivered directly to the lungs.
Cisiv’s technology platform is fit-for-purpose and enables Pharmaceutical and Medical Device companies to collect and manage safety and efficacy studies in the real world. Through our technology, organizations are able to expand their global reach and provide access to more patients. The platform, Baseline plus, spans every aspect of data collection and analysis as well as complex workflows for stakeholder engagement. This intuitive, modular web-based platform is highly configurable, providing unrivalled flexibility, no matter the scope or scale and has proven to reduce data management costs by 60%. Baseline Plus is an industry leading platform, including EDC, eConsent, ePRO, eCOA, eDiary, Surveys, Safety, e-Source, with functionality suitable for site-based, decentralized, and hybrid research. Currently, Cisiv’s intelligent platform is utilized by 90% of the top global pharmaceutical companies and has supported 200+ projects with pharma and biotech organizations.
